Ferroquine

Ferroquine (Ferrochloroquine), a ferrocenyl analogue of Chloroquine, is an antimalarial agent. Ferroquine shows parasiticidal effect on Plasmodium by inducing oxidative stress and the subsequent destruction of the membrane.

Product information

CAS Number: 185055-67-8

Molecular Weight: 433.75

Formula: C23H24ClFeN3

Chemical Name: λ²-iron(2+) 3-{[(7-chloroquinolin-4-yl)amino]methyl}-4-[(dimethylamino)methyl]cyclopenta-1,3-dien-1-ide cyclopenta-1,3-dien-1-ide

Smiles: [Fe+2].CN(C)CC1C[C-]=CC=1CNC1=CC=NC2=CC(Cl)=CC=C21.[C-]1CC=CC=1

InChiKey: DLYPREQTTOHKSM-UHFFFAOYSA-N

InChi: InChI=1S/C18H19ClN3.C5H5.Fe/c1-22(2)12-14-5-3-4-13(14)11-21-17-8-9-20-18-10-15(19)6-7-16(17)18;1-2-4-5-3-1;/h4,6-10H,5,11-12H2,1-2H3,(H,20,21);1-3H,4H2;/q2*-1;+2

Technical Data

Appearance: Solid Power

Purity: ≥98% (or refer to the Certificate of Analysis)

Solubility: DMSO : 8.33 mg/mL (19.20 mM; Need ultrasonic).

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical or refer to Certificate of Analysis

Storage Condition: Dry, dark and -20 ^oC for 1 year or refer to the Certificate of Analysis.

Shelf Life: ≥12 months if stored properly.

Stock Solution Storage: 0 - 4 ^oC for 1 month or refer to the Certificate of Analysis.

Drug Formulation: To be determined

HS Tariff Code: 382200

How to use

In Vitro:

Ferroquine shows cytotoxicity against non-cancerous MRC-5 and HeLa cancer cells with IC50 values of 24.4 µM and 16.8 µM, respectively. 24 hours post-incubation all newly transformed schistosomula (NTS) exposed to 33.3 µM Ferroquine shows strongly reduced viabilities.

In Vivo:

Treatment of mice with 200 and 800 mg/kg Ferroquine, shows low total worm burden reductions of 19.4% and 35.6%. One of the mice treated with 800 mg/kg Ferroquine died within 24 hours post-treatment. No activity is observed treating mice with RQ at 200 mg/kg. Finally, a total worm burden reduction of 17.3% is observed following treatment with FQ-OH. Hence, modification of Chloroquine (CQ) by a ferrocenyl or ruthenocenyl fragment does not increase the antischistosomal properties of CQ. For comparison, at 200 mg/kg mefloquine (MQ) achieves a much higher worm burden reduction of 72.3% in S. mansoni-infected mice. A higher effect against female adult S. mansoni is also observed in MQ treated mice pointing to a sex-specific interference of these drugs with the target. Furthermore, in one of the FQ-OH treated mice many dead worms are recovered and a hepatic shift (i.e. worms migrating to the liver) observed. Hence, Ferroquine and FQ-OH show weak antischistosomal activity in vivo.

Products are for research use only. Not for human use.